Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
therapeutic autologous dendritic cells · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Biological/Vaccine | EXPERIMENTAL | Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product. |
| Name | Type | Description |
|---|---|---|
| therapeutic autologous dendritic cells | BIOLOGICAL | Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product. |
DISEASE CHARACTERISTICS: * Histologically confirmed stage IV or recurrent melanoma * Metastatic disease confirmed by MRI or CT scan * Planned resection of tumor * No active CNS metastases * Radiographically confirmed lack of CNS disease progression * No requirement for pharmacologic doses o...
Top 20 of 51 competitors
Therapeutic autologous dendritic cells is an investigational cell-based vaccine being studied for the treatment of melanoma, specifically in patients with stage IV or recurrent melanoma. It is currently in Phase 1 clinical development and has not been approved by the FDA.
Therapeutic autologous dendritic cells is being developed by Lisata Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol LSTA. The company is conducting clinical research to evaluate this investigational therapy for melanoma.
Therapeutic autologous dendritic cells is in Phase 1 clinical development. It is an investigational therapy, meaning it has not yet been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains under evaluation for safety and efficacy.
Therapeutic autologous dendritic cells has been studied in one completed Phase 1 clinical trial, identified as NCT00012064, titled "Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma." This trial enrolled 56 participants in the United States and was not randomized or blinded.
Therapeutic autologous dendritic cells is a type of vaccine therapy, as indicated by the clinical trial title. It is designed to treat melanoma by using the patient's own dendritic cells, which are modified and administered to stimulate an immune response against cancer cells.